Latest Articles

Publication Date
All News Scientific
Endometrial Cancer: Counseling on dMMR vs pMMR - Explaining Survival Advantage and Clinical Expectations - OncLive

Endometrial Cancer: Counseling on dMMR vs pMMR - Explaining Survival Advantage and Clinical Expectations OncLive

Published: Dec. 26, 2025, 1:19 p.m.
Read Full Article
After comparing endometrial cancer minimally invasive surgery, laparotomy, survival rate and complications... - MSN

After comparing endometrial cancer minimally invasive surgery, laparotomy, survival rate and complications... MSN

Published: Dec. 25, 2025, 7:50 p.m.
Read Full Article
Adjuvant Chemoradiotherapy Provides Long-Term Survival Benefits in High-Risk Endometrial Cancer - OncLive

Adjuvant Chemoradiotherapy Provides Long-Term Survival Benefits in High-Risk Endometrial Cancer OncLive

Published: Dec. 22, 2025, 5:26 a.m.
Read Full Article
The effect of para-aortic lymphadenectomy on survival in early stage endometrioid grade 3 and non-endometrioid endometrial cancers - BMC Women's Health

The effect of para-aortic lymphadenectomy on survival in early stage endometrioid grade 3 and non-endometrioid endometrial cancers BMC Women's Health

Published: Nov. 19, 2025, 11:24 a.m.
Read Full Article
KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer - Indian Pharma Post

KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer Indian Pharma Post

Published: Oct. 22, 2025, 5:03 p.m.
Read Full Article
Tecentriq Plus Chemo Shows Comparable Survival in Endometrial Cancer - CUREtoday.com

Tecentriq Plus Chemo Shows Comparable Survival in Endometrial Cancer CUREtoday.com

Published: Oct. 19, 2025, 6:39 p.m.
Read Full Article
Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer - CancerNetwork

Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer CancerNetwork

Published: Oct. 19, 2025, 4:40 p.m.
Read Full Article
Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer - cancernetwork.com

Atezolizumab Combo Displays Noninferior Survival in Endometrial Cancer cancernetwork.com

Published: Oct. 19, 2025, 4:40 p.m.
Read Full Article
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.
Read Full Article
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!